Literature DB >> 7036552

Chemotherapy of non-small cell lung cancer: clinical trials at the Memorial Sloan-Kettering Cancer Center.

R J Gralla, R E Wittes, E S Casper, D P Kelsen, E Cvitkovic, G B Magill, S E Krown, R B Golbey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7036552     DOI： 10.1007/bf01657925

Source DB:  PubMed          Journal:  World J Surg        ISSN： 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  27 in total

1.  MACC (methotrexate, adriamycin, cyclophosphamide and CCNU) in advanced lung cancer.

Authors:  A P Chahinian; E M Mandel; J F Holland; I S Jaffrey; A S Teirstein
Journal:  Cancer       Date:  1979-05       Impact factor: 6.860

2.  Phase II evaluation of cis-diamminedichloroplatinum(II) in lung cancer.

Authors:  A H Rossof; J D Bearden; C A Coltman
Journal:  Cancer Treat Rep       Date:  1976-11

3.  Lung cancer: to operate or not?

Authors:  C Mittman; I Bruderman
Journal:  Am Rev Respir Dis       Date:  1977-09

4.  Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Guérin or Corynebacterium parvum in stage III lung cancer.

Authors:  S Bjornsson; H Takita; N Kuberka; H Preisler; H Catane; D Higby; E Henderson
Journal:  Cancer Treat Rep       Date:  1978-04

5.  Therapy of advanced squamous carcinoma of the lung: cyclophosphamide vesus "COMB".

Authors:  G P Bodey; S W Lagakos; A C Gutierrez; H E Wilson; O S Selawry
Journal:  Cancer       Date:  1977-03       Impact factor: 6.860

6.  Survival with inoperable lung cancer: an integration of prognostic variables based on simple clinical criteria.

Authors:  V J Lanzotti; D R Thomas; L E Boyle; T L Smith; E A Gehan; M L Samuels
Journal:  Cancer       Date:  1977-01       Impact factor: 6.860

7.  5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for adenocarcinoma of the lung.

Authors:  T P Butler; J S MacDonald; F P Smith; L F Smith; P V Woolley; P S Schein
Journal:  Cancer       Date:  1979-04       Impact factor: 6.860

8.  Evaluation of methotrexate in the treatment of bronchogenic carcinoma.

Authors:  R G Vincent; J W Pickren; T B Fergen; H Takita
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

9.  cis-Dichlorodiammineplatinum(II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung.

Authors:  J C Britell; R T Eagan; J N Ingle; E T Creagen; J Rubin; S Frytak
Journal:  Cancer Treat Rep       Date:  1978-08

10.  Comparative trial of combination chemotherapy in extensive squamous carcinoma of the lung: a Southwest Oncology Group Study.

Authors:  R B Livingston; L Helibrun; D Lehane; J J Costanzi; R Bottomley; R L Palmer; W J Stuckey; B Hoogstraten
Journal:  Cancer Treat Rep       Date:  1977-12
View more
  2 in total

Review 1.  Combination chemotherapy for advanced adenocarcinoma of the lung. A review.

Authors:  J B Sørensen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 2.  Lung cancer--current concepts and controversies.

Authors:  S B Pett; J A Wernly; B F Akl
Journal:  West J Med       Date:  1986-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.